Page 133 - 2019年2月第30卷第4期

solution research：from Noyes and Whitney to the biophar- ing modified USP dissolution apparatus Ⅰ[J]. Drug Dev
maceutics classification system[J]. Int J Pharm，2006，321 Ind Pharm，2011，37（2）：178-184.
（1/2）：1-11. [20] MODI S，ANDERSON BD. Determination of drug release
[ 5 ] D’SOUZA S. A review of in vitro drug release test me- kinetics from nanoparticles：overcoming pitfalls of the dy-
thods for nano-sized dosage forms[J]. Adv in Pharm， namic dialysis method[J]. Mol Pharm，2013，10（8）：
2014. DOI：10.1155/2014/304757. 3076-3089.
[ 6 ] 谢元彪，岳鹏飞，但济修，等.纳米制剂体外释放度评价方 [21] XU X，KHAN MA，BURGESS DJ. A two-stage reverse di-
法的研究进展[J].中国药学杂志，2016，51（11）：861-866. alysis in vitro dissolution testing method for passive tar-
[ 7 ] PENG Q，WEI XQ，YANG Q，et al. Enhanced biostability geted liposomes[J]. Int J Pharm，2012，426（1/2）：211-
of nanoparticle-based drug delivery systems by albumin 218.
corona[J]. Nanomedicine：Lond，2015，10（2）：205-214. [22] WANG JX，SUN X，ZHANG ZR. Enhanced brain target-
[ 8 ] SHEN J，BURGESS DJ. In vitro dissolution testing strate- ing by synthesis of 3′，5′- dioctanoyl-5-fluoro-2′-deoxyuri-
gies for nanoparticulate drug delivery systems：recent de- dine and incorporation into solid lipid nanoparticles[J].
velopments and challenges[J]. Drug Deliv Transl Res， Eur J Pharm Biopharm，2002，54（3）：285-290.
2013，3（5）：409-415. [23] AMOOZGAR Z，PARK J，LIN Q，et al. Low molecular-
[ 9 ] JAIN P，PAWAR RS，PANDEY RS，et al. In-vitro in-vivo weight chitosan as a pH-sensitive stealth coating for tu-
correlation（IVIVC）in nanomedicine：is protein corona the mor-specific drug delivery[J]. Mol Pharm，2012，9（5）：
missing link?[J]. Biotechnol Adv，2017，35（7）：889-904. 1262-1270.
[10] POURJAVADI A，TEHRANI ZM，MAHMOUDI N. The [24] ABOUELMAGD SA，SUN B，CHANG AC，et al. Release
effect of protein corona on doxorubicin release from the kinetics study of poorly water-soluble drugs from nanopar-
magnetic mesoporous silica nanoparticles with polyethy- ticles：are we doing it right？ [J]. Mol Pharm，2015，12
lene glycol coating[J]. J Nanopart Res，2015，17（4）： （3）：997-1003.
197-211. [25] D’SOUZA SS，DELUCA PP. Methods to assess in vitro
[11] CARACCIOLO G. Liposome-protein corona in a physio- drug release from injectable polymeric particulate systems
logical environment：challenges and opportunities for tar- [J]. Pharm Res，2006，23（3）：460-474.
geted delivery of nanomedicines[J]. Nanomedicine，2015， [26] SIEVENS-FIGUEROA L，PANDYA N，BHAKAY A，et al.
11（3）：543-557. Using USP Ⅰ and USP Ⅳ for discriminating dissolution
[12] CHO EJ，HOLBACK H，LIU KC，et al. Nanoparticle char- rates of nano-and microparticle-loaded pharmaceutical strip-
acterization：state of the art，challenges，and emerging films[J]. AAPS Pharm Sci Tech，2012，13（4）：1473-1482.
technologies[J]. Mol Pharm，2013，10（6）：2093-2110. [27] HENG D，CUTLER DJ，CHAN HK，et al. What is a suit-
[13] ZENG L，AN L，WU X. Modeling drug-carrier interac- able dissolution method for drug nanoparticles?[J]. Pharm
tion in the drug release from nanocarriers[J]. J Drug De- Res，2008，25（7）：1696-1701.
liv，2011. DOI：10.1155/2011/370308. [28] SUN B，TAHA MS，RAMSEY B，et al. Intraperitoneal
[14] NIE S. Understanding and overcoming major barriers in chemotherapy of ovarian cancer by hydrogel depot of pa-
cancer nanomedicine[J]. Nanomedicine：Lond，2010，5（4）： clitaxel nanocrystals[J]. J Control Release，2016，235（8）：
523-528. 91-98.
[15] ZAMBITO Y，PEDRESCHI E，DI COLO G. Is dialysis a [29] BOYD BJ. Characterisation of drug release from cubo-
reliable method for studying drug release from nanopartic- somes using the pressure ultrafiltration method[J]. Int J
ulate systems？ A case study[J]. Int J Pharm，2012，434 Pharm，2003，260（2）：239-247.
（1/2）：28-34. [30] WALLACE SJ，LI J，NATION RL，et al. Drug release
[16] SEZER AD，AKBUĞA J，BAŞ AL. In vitro evaluation of from nanomedicines：selection of appropriate encapsula-
enrofloxacin-loaded MLV liposomes[J]. Drug Deliv，2007， tion and release methodology[J]. Drug Deliv Transl Res，
14（1）：47-53. 2012，2（4）：284-292.
[17] 王智勇，张金录，陈岩，等.3 种香豆素 6 纳米微粒的制备 [31] ORASUGH JT，SAHA NR，SARKAR G，et al. Synthesis
及其体外释药特性研究[J].中国药房，2012，23（45）： of methylcellulose/cellulose nano-crystals nanocompo-
4266-4268. sites：material properties and study of sustained release of
[18] ABDEL-MOTTALEB MM，NEUMANN D，LAMPRE- ketorolac tromethamine[J]. Carbohydr Polym，2018，188
CHT A. In vitro drug release mechanism from lipid nano- （5）：168-180.
capsules（LNC）[J]. Int J Pharm，2010，390（2）：208-213. [32] ANDREANI T，DE SOUZA AL，KIILL CP，et al. Prepara-
[19] ABDEL-MOTTALEB MM，LAMPRECHT A. Standard- tion and characterization of PEG-coated silica nanoparti-
ized in vitro drug release test for colloidal drug carriers us- cles for oral insulin delivery[J]. Int J Pharm，2014，473

·552 · China Pharmacy 2019 Vol. 30 No. 4 中国药房 2019年第30卷第4期